Logo

Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous Polyposis (FAP)

Share this

Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous Polyposis (FAP)

Shots:

  • Janssen has initiated P-Ib proof-of-concept clinical trial assessing Guselkumab vs PBO in 72 patients with familial adenomatous polyposis (FAP). With the initiation of P-Ib study for FAP- MorphoSys will receive milestones from Janssen
  • Earlier- Janssen collaborated with MorphoSys to develop Guselkumab utilizing MorphoSys's HuCAL antibody technology (Human Combinatorial Antibody Library)- a platform for invitro generation of Abs
  • Tremfya(R) (guselkumab) is an anti-IL-23 mAb and has received approval in the US- Canada- EU for plaque psoriasis and in Japan for psoriasis- psoriatic arthritis & palmoplantar pustulosis

Ref: MorphoSys | Image: Janssen 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions